# US 2011/0257257 A1 · Composition for treatment of epithelial tissue

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0257257 A1
- Document ID: US20110257257A1
- Status: Published application
- Kind: A1
- Application number: 13/091,165
- Filed: 2011-04-21
- Published: 2011-10-20
- Earliest claimed: 2008-10-21
- Assignees: Novodermix International Limited
- Inventors: Nathan Andrew SHAPIRA; Amir Barzilay
- Web page: https://patentgrep.com/patent/US20110257257A1

## CPC

- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 9/107: Emulsions {; Emulsion preconcentrates; Micelles (composition of emulsions A61K47/00)}
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/357: having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/16: Emollients or protectives, e.g. against radiation
- A61P 27/02: Ophthalmic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition is provided. The composition is a topical oil-in-water formulation which includes a GABA agonist such as topiramate as the active ingredient.

## Claims

### Claim 1

A pharmaceutical composition comprising a GABA agonist and an oil-in-water carrier.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein said GABA agonist is Topiramate.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2, wherein the pharmaceutical composition includes 0.1-7.5% (w/w) of said Topiramate.

### Claim 4 (depends on 2)

The pharmaceutical composition of claim 2, wherein the pharmaceutical composition includes 0.5-5.0% (w/w) of said Topiramate.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein said composition includes a moisturizing agent.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein said composition includes a skin penetration enhancer.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition includes water, white soft paraffin, cetosteary alcohol, liquid paraffin and sodium lauryl sulfate.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein the composition includes water, dimethicone, stearic acid, isopropyl myristate, mineral oil, glycerin, glyceryl stearate, cetyl alcohol, pentenol and TEA.

### Claim 9

A method of treating a disorder associated with epithelial tissue comprising topically applying a pharmaceutical composition comprising a GABA agonist and an oil-in-water carrier to said epithelial tissue thereby treating the disorder.

### Claim 10 (depends on 9)

The method of claim 9, wherein said oil-in-water carrier is formulated as a cream, a gel cream an emulsion or a foam.

### Claim 11 (depends on 9)

The method of claim 9, wherein said epithelial tissue is skin.

### Claim 12 (depends on 9)

The method of claim 9, wherein said disorder is a wound.

### Claim 13 (depends on 9)

The method of claim 9, wherein said disorder is a scar.

### Claim 14 (depends on 9)

The method of claim 9, wherein said disorder is caused by skin atrophy.

### Claim 15 (depends on 9)

The method of claim 9, wherein GABA agonist is topiramate.

### Claim 16 (depends on 15)

The method of claim 15, wherein said pharmaceutical composition includes 0.1-7.5% (w/w) of said topiramate.

### Claim 17 (depends on 13)

The method of claim 13, wherein said scar is an atrophic scar or depressed scar.

### Claim 18 (depends on 9)

The method of claim 9, wherein the disorder is a wound and said pharmaceutical composition is first applied 0-8 days following wounding.

### Claim 19

A method of reducing the appearance of a scar or minimizing scar formation comprising topically applying a pharmaceutical composition comprising Topiramate to tissue having a wound or scar.
